Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
20 hedge funds and large institutions have $7.92M invested in Evoke Pharma in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
67% more capital invested
Capital invested by funds: $4.76M → $7.92M (+$3.17M)
0.03% more ownership
Funds ownership: 0.1% → 0.13% (+0.03%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.65M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$79.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$49.1K |
| 4 |
VF
Virtu Financial
New York
|
+$40.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$416K |
| 2 |
JGC
J. Goldman & Co
New York
|
-$52K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$11K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.37K |
EVOK Hedge Fund Activity: Q2 2018 in Review
20 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2018, worth a combined $7.92M — up 67% from $4.76M a quarter earlier.
Fund positioning in EVOK was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $2.65M. The largest seller was Deutsche Bank, exiting entirely with an estimated $416K sold.
- 20 institutional investors held Evoke Pharma (EVOK) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $7.92M of Evoke Pharma stock for Q2 2018, up 67% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q2 2018 and 3 closed out, a net change of 0 holders.
- The largest Evoke Pharma buyer in Q2 2018 was Sphera Funds Management, an estimated $2.65M added.
- The largest Evoke Pharma seller in Q2 2018 was Deutsche Bank, an estimated $416K sold.
Based on aggregated 13F filings for Q2 2018.